Valeant to sell assets for $2.12 billion to ease debt load
(Reuters) - Valeant Pharmaceuticals International is selling its Dendreon cancer business and three skincare brands for about $2.12 billion as the troubled Canadian drugmaker looks to pay down its more than $30 billion debt.
No comments:
Post a Comment